Effect of free and in poly(ε-caprolactone) nanoparticles incorporated new type 1 17β-hydroxysteroid dehydrogenase inhibitors on cancer cells

Current Nanoscience

Volumn 6, Issue 1, 2010, Pages 69-76

  Kocbek, Petra ^a   Teskač, Karmen ^a   Brožič, Petra ^a   Rižner, Tea Lanišnik ^a   Gobec, Stanislav ^a   Kristl, Julijana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Breast cancer; Cellular uptake; Drug delivery; Enzyme inhibitors; Nanoparticles; T 47D cells

Indexed keywords

ANTICANCER ACTIVITIES; AQUEOUS MEDIUM; BIOLOGICAL ACTIVITIES; BIOLOGICAL EFFECTS; BREAST CANCER; BREAST CANCER CELLS; CANCER CELLS; CAPROLACTONE; CELL CYTOPLASM; CELL VIABILITY; CELLULAR UPTAKE; DELIVERY SYSTEMS; ENTRAPMENT EFFICIENCY; ENZYME INHIBITORS; HYDROXYSTEROID DEHYDROGENASE; IN-CELL; MEAN DIAMETER; SPHERICAL SHAPE; TRANS-CINNAMIC ACID; WATERSOLUBLE;

BIOCHEMISTRY; CELL PROLIFERATION; DRUG DELIVERY; ESTERS; NANOPARTICLES; POLYDISPERSITY; SYSTEM STABILITY; ZETA POTENTIAL;

ENZYMES;

BENZYL 3 PHENYLPROP 2 ENOATE; CINNAMIC ACID DERIVATIVE; ENZYME INHIBITOR; NANOPARTICLE; PHENYL 3 (3,4,5 TRIMETHOXYPHENYL)PROP 2 ENOATE; POLYCAPROLACTONE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG LABELING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ZETA POTENTIAL;

EID: 77950406126     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341310790226397     Document Type: Article

References (29)

1. Cadot, C.; Laplante, Y.; Kamal, F.; Luu-The, V.; Poirier, D. C6-(N,N-butylmethyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation. Bioorg. Med. Chem., 2007, 15(2), 714-726.
2. Chetrite, G.S.; Pasqualini, J.R. The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem. Mol. Biol., 2001, 76(1-5), 95-104.
3. Labrie, V.L.-T.F.; Lin, S.X.; Simard, J.; Labrie, C.; El-Alfy, M.; Pelletier, G.; Belanger, A. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 2000, 25(1), 1-16.
4. Miettinen, M.M.; Mustonen, M.V.; Poutanen, M.H.; Isomaa, V.V.; Vihko, R.K. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem. J., 1996, 314, 839-845.
5. Törn, S.; Nokelainen, P.; Kurkela, R.; Pulkka, A.; Menjivar, M.; Ghosh, S.; Coca-Prados, M.; Peltoketo, H.; Isomaa, V.; Vihko, P. Production, purification, and functional analysis of recombinant human and mouse 17β-hydroxysteroid dehydrogenase type 7. Biochem. Biophys. Res. Commun., 2003, 305(1), 37-45.
6. Song, D.; Liu, G.; Luu-The, V.; Zhao, D.; Wang, L.; Zang, H.; Xueling, G.; Li, S.; Desy, L.; Labrie, F.; Pelletier, G. Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer: An immunocytochemical study. J. Steroid Biochem. Mol. Biol., 2006, 101(2-3), 136-144.
7. Duncan, L.J.; Reed, M.J. The role and proposed mechanism by which oestradiol 17β-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations. J. Steroid Biochem. Mol. Biol., 1995, 55(5-6), 565-572.
8. Miettinen, M.M.; Mustonen, M.; Poutanen, M.; Isomaa, V.; Wickman, M.; Söderqvist, G.; Vihko, R.; Vihko, P. 17β-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res. Treat., 1999, 57(2), 175-182.
9. Pasqualini, J.R.; Chetrite, G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol., 2005, 93(2-5), 221-236.
10. Irahara, N.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Quantitative analysis of aromatase, sulfatase and 17β-HSD1 mRNA expression in soft tissue metastases of breast cancer. Cancer Lett., 2006, 243(1), 23-31.
11. Poirier, D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem., 2003, 10(6), 453-477.
12. Brožič, P.; Lanišnik Rižner, T.; Gobec, S. Inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem., 2008, 15(2), 137-150.
13. Bala, I.; Hariharan, S.; Kumar, M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst., 2004, 21(5), 387-422.
14. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2(3), 14-21.
15. Chawla, J.S.; Amiji, M.M. Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm., 2002, 249(1-2), 127-138.
16. Cegnar, M.; Kristl, J.; Kos, J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin. Biol. Ther., 2005, 5(12), 1557-1569.
17. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release, 2007, 120(1-2), 18-26.
18. Pasqualini, J.R. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta CR Rev. Cancer, 2004, 1654(2), 123-143.
19. Kristan, K.; Starčevič, Š.; Brunskole, M.; Lanišnik Rižner, T.; Gobec, S. Cinnamates and cinnamamides inhibit fungal 17β-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol., 2006, 248(1-2), 239-241.
20. Sova, M.; Perdih, A.; Kotnik, M.; Kristan, K.; Lanišnik Rižner, T.; Šolmajer, T.; Gobec, S. Flavonoids and cinnamic acid esters as inhibitors of fungal 17β-hydroxysteroid dehydrogenase: A synthesis, QSAR and modelling study. Bioorg. Med. Chem., 2006, 14(22), 7404-7418.
21. Husen, B.; Huhtinen, K.; Poutanen, M.; Kangas, L.; Messinger, J.; Thole, H. Evaluation of inhibitors for 17β-Hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol. Cell. Endocrinol., 2006, 248(1-2), 109-113.
22. Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm., 2008, 69(1), 1-9.
23. Shenoy, D.B.; Amiji, M.M. Poly(ethylene oxide)-modified poly(ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 2005, 293(1-2), 261-270.
24. Panyam, J.; Sahoo, S.K.; Prabha, S.; Bargar, T.; Labhasetwar, V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int. J. Pharm., 2003, 262(1-2), 1-11.
25. Villemson, A.; Couvreur, P.; Gillet, B.; Larionova, N.; Gref, R. Dextranpoly-ε-caprolactone micro- and nanoparticles: preparation, characterization and tamoxifen solubilization. J. Drug Deliv. Sci. Technol., 2006, 16(4), 307-313.
26. Panyam, J.; Labhasetwar, V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharm., 2004, 1(1), 77-84.
27. Chawla, J.S.; Amiji, M.M. Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles. AAPS PharmSci., 2003, 5(1), article 3.
28. Cegnar, M.; Premzl, A.; Zavažnik-Bergant, V.; Kristl, J.; Kos, J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res., 2004, 301(2), 223-231.
29. Day, J.M.; Tutill, H.J.; Newman, S.P.; Purohit, A.; Lawrence, H.R.; Vicker, N.; Potter, B.V.L.; Reed, M.J. 17β-hydroxysteroid dehydrogenase type 1 and type 2: Association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol., 2006, 248(1-2), 246-249.